Inj anifrolumab-fnia 1mg
Products billed under this code include Saphnelo.
Payment limit per 1 MG, by effective quarter, 2Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Saphnelo.
Payment limit per 1 MG, by effective quarter, 2Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Saphnelo | AstraZeneca Pharmaceuticals LP | 00310-3040-00 | 300 | $5,538.30 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $18.461 | −$0.047 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted September 17, 2026 |
| 3Q26 | $18.508 | +$0.201 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted September 15, 2026 |
| 2Q26 | $18.307 | −$0.031 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted September 15, 2026 |
| 1Q26 | $18.338 | +$0.259 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted September 15, 2026 |
| 4Q25 | $18.079 | −$0.025 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted September 8, 2026 |
| 3Q25 | $18.104 | +$0.327 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted March 10, 2026 |
| 2Q25 | $17.777 | +$0.014 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted March 10, 2026 |
| 1Q25 | $17.763 | +$0.472 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted December 19, 2025 |
| 4Q24 | $17.291 | −$0.04 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted June 11, 2025 |
| 3Q24 | $17.331 | +$0.196 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted June 11, 2025 |
| 2Q24 | $17.135 | −$0.045 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted March 11, 2025 |
| 1Q24 | $17.18 | +$0.585 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted December 19, 2024 |
| 4Q23 | $16.595 | −$0.061 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted October 10, 2024 |
| 3Q23 | $16.656 | +$0.431 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted June 5, 2024 |
| 2Q23 | $16.225 | −$0.091 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted February 23, 2024 |
| 1Q23 | $16.316 | +$0.156 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted December 6, 2023 |
| 4Q22 | $16.16 | −$0.017 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted June 22, 2023 |
| 3Q22 | $16.177 | −$0.03 | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted June 9, 2023 |
| 2Q22 | $16.207 | – | 1 MG | Inj anifrolumab-fnia 1mg | v1, posted December 14, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.